Accounting for quiescent cells in tumour growth and cancer treatment

IEE Proceedings Systems Biology

Volumn 152, Issue 4, 2005, Pages 185-192

  Florian Jr , J A ^a   Eiseman, J L ^b,c   Parker, R S ^a,c  

^a University of Pittsburgh   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

Cancer; Cancer treatment; Cellular biophysics; Chemotherapeutic tamoxifen; Controllers; Drugs; Four state cell cycle model; G1 phase representation; Open loop analysis; Patient treatment; Physiological models; Quiescent cell controller; Tumour growth; Tumours

Indexed keywords

ALGORITHMS; CHEMOTHERAPY; COMPUTER SIMULATION; MATHEMATICAL MODELS; ONCOLOGY; ORDINARY DIFFERENTIAL EQUATIONS; PHARMACODYNAMICS; TUMORS;

CHEMOTHERAPEUTIC TAMOXIFEN; NONLINEAR MODEL PREDICTIVE CONTROL; QUIESCENT CELLS; TUMOUR GROWTH;

CELLS;

TAMOXIFEN; TOPOTECAN;

ACCURACY; ALGORITHM; ARTICLE; BIOLOGICAL MODEL; CANCER; CANCER CELL; CANCER GROWTH; CELL CYCLE G1 PHASE; CLINICAL PROTOCOL; COMPARTMENT MODEL; FLOW CYTOMETRY; HUMAN; NONHUMAN; PHARMACODYNAMICS; PREDICTION; SENSITIVITY ANALYSIS; SIMULATION; SOLID TUMOR; TUMOR XENOGRAFT;

ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CELL CYCLE; CELL CYCLE PROTEINS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMPUTER-ASSISTED; HUMANS; MICE; MODELS, BIOLOGICAL; NEOPLASM PROTEINS; SIGNAL TRANSDUCTION; TAMOXIFEN;

EID: 31144447291     PISSN: 17412471     EISSN: None     Source Type: Journal    
DOI: 10.1049/ip-syb:20050041     Document Type: Article

References (25)

1. 'Cancer facts & figures: 2005', (The American Cancer Society 2005), http://www.cancer.org/downloads/STT/CAFF2005f4PWSecured.pdf
2. D'Argenio, D.Z., and Schumitzky, A.: 'ADAPT II users guide: Pharmacokinetic and pharmacodynamic systems analysis software, biomedical simulations resource', (University of Southern California, Los Angeles, CA 1997)
3. Minami, H.: 'A point, a line, or an area? Which is the most important in the pharmacological analysis of cancer chemotherapy?' J. Clin. Oncol., 2005, 23, (3), p. 405-406
4. Martin, R.B.: 'Optimal control drug scheduling of cancer chemotherapy', Automatica, 1992, 28, p. 1113-1123 10.1016/0005-1098(92)90054-J 0005-1098
5. Panetta J.C., and Adam, J.: 'A mathematical model of cycle-specific chemotherapy', Math. Comput. Model., 1995, 22, (2), p. 67-82 0895-7177
6. Harrold, J.M., Eiseman, J.L., Zamboni, W.C., and Parker, R.S.: 'Modeling of toxicity effects and nonlinearities in pharmacokinetics of 9-nitrocamptothecin in mice', AIChE Annual Meeting, Austin, TX 2004
7. Ledzewicz, U., and Schättler, H.: 'Optimal bang-bang controls for a two-compartment model in cancer chemotherapy', J. Optim. Theory Appl., 2002, 114, (3), p. 609-637 10.1023/A:1016027113579 0022-3239
8. Ellis, M.J., and Swain, S.M.: 'Steroid hormone therapies for cancer', Chabner, B.A., Longo, D.L., Cancer chemotherapy and biotherapy: principles and practice, 3rd (Lippincott Williams and Wilkins 2001), p. 103-113
9. Robinson, S.P., Langan-Fahey, S.M., Delinda, A.J., and Jordan, V.C.: 'Metabolites, pharmacodynamics, and pharmacokinetics of tamoxifen in rats and mice compared to the breast cancer patient', Drug Metab. Dispos., 1991, 19, (1), p. 36-43
10. Florian, J.A., Eiseman, J.L., and Parker, R.S.: 'A nonlinear model predictive control algorithm for breast cancer treatment', Proc. DYCOPS 7, Boston, MA 2004, p. 1-12
11. Conley, B.A., Ramsland, T.S., Sentz, D.L., Wu, S., Rosen, D.M. Wollman, M., and Eiseman, J.L.: 'Antitumour activity, distribution, and metabolism of 13- cis -retinoic acid as a single agent or in combination with tamoxifen in established human MCF-7 xenografts in mice', Cancer Chemother. Pharmacol., 1999, 43, p. 183-197
12. Martin, R., and Teo, K.L.: 'Optimal control of drug administration in cancer chemotherapy', (World Scientific, River Edge, NJ)1994
13. Norton, L.: 'A Gompertzian model of human breast cancer growth', Cancer Res., 1988, 48, p. 7067-7071
14. Lopes, N.M., Adams, E.G., and Bhuyan, B.K.: 'Cell kill kinetics and cell cycle effects of Taxol on human and hamster ovarian cell lines', Cancer Chemothers Pharmacol., 1993, 32, (3), p. 235-242
15. Takimoto, C.H., and Arbuck, S.G.: 'Topoisomerase I targeting agents: The camptothecins', Chabner, B.A., Longo, D.L., Cancer chemotherapy & biology, 3rd (Lippincott Williams & Wilkins 2001), 20, p. 579-646
16. Lee, G.S., Ryu, K.S., Kim, S.P., Namkoong, S.E., and Han, K.T. 'Multiparametric flow cytometric analysis in a breast cancer cell line (MCF-7)', J. Obstet. Gynaecol. Res., 2002, 28, (3), p. 141-148
17. Riesberg, M., Kasper, C., Reardon, K.F., and Scheper, T.: 'Flow cytometry in biotechnology', Appl. Microbiol. Biotechnol., 2001, 56, p. 350-360
18. Shapiro, H.M.: 'Practical flow cytometry', 4th (Wiley-Liss, Hoboken, New Jersey 2003)
19. Akaike, H.: 'A Bayesian extension of the minimal AIC procedures of autoregressive model fitting', Biometrika, 1979, 66, p. 237 0006-3444
20. Morari, M., and Zafiriou, E.: 'Robust process control', (Prentice-Hall, Englewood Cliffs, NJ 1989)
21. Martin, E.A., Carthew, P., White, I.N., Heydon, R.T., Gaskell, M., Mauthe, R.J., Turteltaub, K.W., and Smith, L.L.: 'Investigation of the formation and accumulation of liver DNA adducts in mice chronically exposed to tamoxifen', Carcinogenesis, 1997, 18, (11), p. 2209-2215
22. Slingerland, J.M., and Tannock, I.F.: 'Cell proliferation and cell death', Tannock, I.F., Hill, R.P., Morgan, J., The basic science of oncology, 3rd (McGraw-Hill 1998), 7, p. 134-165
23. Eslami, M.: 'Theory of sensitivity in dynamic systems', (Springer-Verlag, Berlin, Germany 1994) 1994
24. Allgöwer, F., Badgwell, T.A., Qin, J.S., Rawlings, J.B., and Wright, S.J.: 'Nonlinear predictive control and moving horizon estimation - an introductory overview, advances in control - highlights of ECC '99', (Springer, London 1999), p. 391-449
25. Morari, M., and Ricker, N.L.: 'Model predictive control toolbox', (The MathWorks, Inc., Natick, MA) 1994